Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

4999 - Independent predictors of one year mortality in patients with primary systemic immunoglobulin light chain cardiac amyloidosis


09 Sep 2017


Poster display session


Cancers in Adolescents and Young Adults (AYA);  Haematological Malignancies


Vijay Srinivasalu


Annals of Oncology (2017) 28 (suppl_5): v355-v371. 10.1093/annonc/mdx373


V. Srinivasalu1, M. Subramaniam2, A. Shanmugam2, A. Philip1, A. Susan1, R. Prabhu3, M. Unni3, N. Sidharthan3, W. Jose1, S. N V4, H. Ahamed2, N. Mathew2, P. Keechilat1

Author affiliations

  • 1 Department Of Medical Oncology, Amrita institute of medical sciences, 682041 - KOCHI/IN
  • 2 Department Of Cardiology, Amrita institute of medical sciences, 682041 - KOCHI/IN
  • 3 Department Of Medical Oncology And Hematology, Amrita institute of medical sciences, 682041 - KOCHI/IN
  • 4 Department Of Pathology, Amrita institute of medical sciences, 682041 - KOCHI/IN


Abstract 4999


Immunoglobulin light chain amyloidosis (AL amyloidosis) is a monoclonal plasma cell proliferative disorder that is characterized by tissue deposits of misfolded insoluble κ and λ light chain derived amyloid fibrils, leading to organ dysfunction. The prognosis of patients depends on the number and severity of organ involvement, especially cardiac involvement. Nearly half of the patients with amyloidosis die within a year of diagnosis. We analysed factors predicting early mortality (within one year) in patients with systemic immunoglobulin light chain cardiac amyloidosis.


Retrospective analysis of patients between January 2007 and January 2016 from our hospital database. In patients with AL cardiac amyloidosis, cardiac involvement was defined as per American society of echocardiography (ASE) criteria. We evaluated the clinical, ECG and ECHO parameters of early relapse (ER) within one year in these cardiac AL amyloidosis patients. Log rank test was done to identify independent predictors of one year all cause mortality.


Among the 72 patients (mean age 58.2 + 8.2 years, 59.7% males) of AL amyloidosis with cardiac involvement, 32 (44.4%) died within one year. Sixty five patients (90%) received melphalan/thalidomide/bortezomib/cyclophosphamide/dexamethasone based chemotherapy as a monotherapy or in combinations. Logistic regression analysis revealed NYHA Class III/IV (p = 0.024), BNP (p = 0.031), Troponin I (p = 0.042), Free light chain difference (p = 0.011) and restrictive pattern of diastolic dysfunction (E/E1 > 20) to be independent predictors of all cause mortality (p = 0.021). Kaplan Meir survival analysis showed a worse prognosis in patients with E/E1 > 20 (Log rank, p 


AL Cardiac amyloidosis carries a poor outcome. Baseline Troponin I, NYHA class III/IV, difference in free light chain, restrictive pattern of diastolic dysfunction and BNP were the independent predictors of early mortality within 1 year in patients with AL cardiac amyloidosis. In patients who completed atleast 6 months of chemotherapy, a decrease in the ECHO parameter E/E1 is associated with better one year survival. This will help us in better prognostication of patients with AL cardiac amyloidosis.

Clinical trial identification

This is not a clinical trial

Legal entity responsible for the study

Amrita institute of medical sciences




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.